{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:20:51Z","timestamp":1764220851297,"version":"3.46.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Outstanding Youth Fund Project of Hunan Province","award":["500000"],"award-info":[{"award-number":["500000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00259-025-07407-8","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:14:12Z","timestamp":1750022052000},"page":"218-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The additive value of 68Ga-RM26 PET\/CT to 68Ga-PSMA\u2212617 PET\/CT in assessing Post-treatment outcomes of ARSIs in mCRPC patients"],"prefix":"10.1007","volume":"53","author":[{"given":"Xuhao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-2064","authenticated-orcid":false,"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"6","key":"7407_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"issue":"4","key":"7407_CR2","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","volume":"130","author":"J Mateo","year":"2020","unstructured":"Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130(4):1743\u201351.","journal-title":"J Clin Invest"},{"issue":"4","key":"7407_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.5534\/wjmh.220200","volume":"41","author":"K Hatano","year":"2023","unstructured":"Hatano K, Nonomura N. Systemic therapies for metastatic castration-resistant prostate cancer: an updated review. World J Men\u2019s Health. 2023;41(4):769\u201384.","journal-title":"World J Men\u2019s Health."},{"issue":"2","key":"7407_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/pcan.2016.71","volume":"20","author":"AH Bryce","year":"2017","unstructured":"Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017;20(2):221\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7407_CR5","doi-asserted-by":"crossref","unstructured":"Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, et al. Prediction of plasma ctdna fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024;15(1):182.","DOI":"10.1038\/s41467-024-45475-w"},{"key":"7407_CR6","doi-asserted-by":"crossref","unstructured":"Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto BF, Palmieri A, et al. Liquid biopsy in prostate cancer management-current challenges and future perspectives. Cancers (Basel). 2022;14(13):3272.","DOI":"10.3390\/cancers14133272"},{"key":"7407_CR7","doi-asserted-by":"crossref","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA-PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651\u201358.","DOI":"10.2967\/jnumed.121.263072"},{"issue":"1","key":"7407_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.262250","volume":"63","author":"R Chen","year":"2022","unstructured":"Chen R, Wang Y, Zhu Y, Shi Y, Xu L, Huang G, et al. The added value of 18F-FDG PET\/CT compared with 68Ga-PSMA PET\/CT in patients with Castration-Resistant prostate Cancer. J Nucl Med. 2022;63(1):69\u201375.","journal-title":"J Nucl Med"},{"issue":"1","key":"7407_CR9","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.clgc.2016.09.002","volume":"15","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ, et al. Correlation of PSMA-Targeted (18)F-DCFPyL PET\/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate Cancer. Clin Genitourin Cancer. 2017;15(1):e65\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"7407_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","volume":"2","author":"SP Thang","year":"2019","unstructured":"Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, et al. Poor outcomes for patients with metastatic Castration-resistant prostate Cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for (177)Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2(6):670\u20136.","journal-title":"Eur Urol Oncol"},{"key":"7407_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","volume":"57","author":"M Crumbaker","year":"2023","unstructured":"Crumbaker M, Goldstein LD, Murray DH, Tao J, Pathmanandavel S, Boulter N, et al. Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate Cancer treated with Lutetium-177-PSMA-617. Eur Urol Open Sci. 2023;57:30\u20136.","journal-title":"Eur Urol Open Sci"},{"key":"7407_CR12","doi-asserted-by":"crossref","unstructured":"Peng S, Zhan Y, Zhang D, Ren L, Chen A, Chen Z-F et al. Structures of human gastrin-releasing peptide receptors bound to antagonist and agonist for cancer and itch therapy. Proc Natl Acad Sci. 2023;120(6).","DOI":"10.1073\/pnas.2216230120"},{"issue":"1","key":"7407_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40644-024-00658-y","volume":"24","author":"Y Ma","year":"2024","unstructured":"Ma Y, Gao F. Advances of radiolabeled GRPR ligands for PET\/CT imaging of cancers. Cancer Imaging. 2024;24(1):19.","journal-title":"Cancer Imaging"},{"issue":"11","key":"7407_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/14737159.2022.2145187","volume":"22","author":"J Gorica","year":"2022","unstructured":"Gorica J, De Feo MS, Filippi L, Frantellizzi V, Schillaci O, De Vincentis G. Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: from pre-clinical studies to translational perspectives. Expert Rev Mol Diagn. 2022;22(11):991\u20136.","journal-title":"Expert Rev Mol Diagn"},{"issue":"10","key":"7407_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"7407_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/iju.14012","volume":"26","author":"L Bianchi","year":"2019","unstructured":"Bianchi L, Schiavina R, Borghesi M, Ceci F, Angiolini A, Chessa F, et al. How does (68) Ga-prostate-specific membrane antigen positron emission tomography\/computed tomography impact the management of patients with prostate cancer recurrence after surgery? Int J Urol. 2019;26(8):804\u201311.","journal-title":"Int J Urol"},{"issue":"2","key":"7407_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate Cancer. Curr Oncol Rep. 2021;23(2):15.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"7407_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2019","unstructured":"Bakht MK, Derecichei I, Li Y, Ferraiuolo R-M, Dunning M, Oh SW, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr-Relat Cancer. 2019;26(2):131\u201346.","journal-title":"Endocr-Relat Cancer"},{"issue":"1","key":"7407_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","volume":"23","author":"W Yu","year":"2023","unstructured":"Yu W, Zhao M, Deng Y, Liu S, Du G, Yan B, et al. Meta-analysis of (18) F-PSMA-1007 PET\/CT, (18) F-FDG PET\/CT, and (68)Ga-PSMA PET\/CT in diagnostic efficacy of prostate Cancer. Cancer Imaging. 2023;23(1):77.","journal-title":"Cancer Imaging"},{"key":"7407_CR20","doi-asserted-by":"crossref","unstructured":"Schollhammer R, Quintyn Ranty M-L, de Clermont Gallerande H, Cavelier F, Valverde IE, Vimont D, et al. Theranostics of primary prostate cancer: beyond PSMA and GRP-R. Cancers. 2023;15(8):2345.","DOI":"10.3390\/cancers15082345"},{"issue":"1","key":"7407_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13014-021-01776-8","volume":"16","author":"P Rogowski","year":"2021","unstructured":"Rogowski P, Roach M 3rd, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021;16(1):50.","journal-title":"Radiat Oncol"},{"issue":"1","key":"7407_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13550-024-01116-3","volume":"14","author":"L Xiao","year":"2024","unstructured":"Xiao L, Fang Z, Tang Y, Sun Y, Zhu Z, Li J, Zhou M, Yang N, Zheng K, Hu S. Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis. EJNMMI Res. 2024;14(1):55.","journal-title":"EJNMMI Res"},{"key":"7407_CR23","doi-asserted-by":"publisher","first-page":"1199432","DOI":"10.3389\/fonc.2023.1199432","volume":"13","author":"M Verhoeven","year":"2023","unstructured":"Verhoeven M, Ruigrok EAM, van Leenders GJLH, van den Brink L, Balcioglu HE, van Weerden WM, Dalm SU. GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches. Front Oncol. 2023;13:1199432.","journal-title":"Front Oncol"},{"issue":"1","key":"7407_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40291-021-00570-2","volume":"26","author":"S Atout","year":"2022","unstructured":"Atout S, Shurrab S, Loveridge C. Evaluation of the suitability of RNAscope as a technique to measure gene expression in clinical diagnostics: A systematic review. Mol Diagn Ther. 2022;26(1):19\u201337.","journal-title":"Mol Diagn Ther"},{"key":"7407_CR25","doi-asserted-by":"publisher","first-page":"679527","DOI":"10.3389\/fcell.2021.679527","volume":"9","author":"Z Gao","year":"2021","unstructured":"Gao Z, Pang B, Li J, Gao N, Fan T, Li Y. Emerging role of exosomes in liquid biopsy for monitoring prostate Cancer invasion and metastasis. Front Cell Dev Biol. 2021;9:679527. https:\/\/doi.org\/10.3389\/fcell.2021.679527.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"7407_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3892\/ol.2024.1468","volume":"28","author":"Q Ge","year":"2024","unstructured":"Ge Q, Zhang ZY, Li SN, Ma JQ, Zhao Z. Liquid biopsy: comprehensive overview of Circulating tumor DNA (Review). Oncol Lett. 2024;28(5):548. https:\/\/doi.org\/10.3892\/ol.2024.1468.","journal-title":"Oncol Lett"},{"key":"7407_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cca.2020.08.007","volume":"510","author":"M Yu","year":"2020","unstructured":"Yu M, Yang C, Wang S, Zeng Y, Chen Z, Feng N, Ning C, Wang L, Xue L, Zhang Z. Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer. Clin Chim Acta. 2020;510:437\u201341.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"7407_CR28","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2967\/jnumed.117.198929","volume":"59","author":"J Zhang","year":"2018","unstructured":"Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, Wu H, Zhu Z, Li F, Chen X. PET using a GRPR antagonist 68Ga-RM26 in healthy volunteers and prostate Cancer patients. J Nucl Med. 2018;59(6):922\u20138.","journal-title":"J Nucl Med"},{"key":"7407_CR29","doi-asserted-by":"crossref","unstructured":"Fernandez R, Soza-Ried C, Iagaru A, Stephens A, Muller A, Schieferstein H, et al. Imaging GRPr expression in metastatic castration-resistant prostate cancer with [(68)Ga]Ga-RM2-A head-to-head pilot comparison with [(68)Ga]Ga-PSMA-11. Cancers (Basel). 2023;16(1):173.","DOI":"10.3390\/cancers16010173"},{"issue":"1","key":"7407_CR30","doi-asserted-by":"publisher","first-page":"2320301","DOI":"10.1080\/07853890.2024.2320301","volume":"56","author":"H Zhang","year":"2024","unstructured":"Zhang H, Qi L, Cai Y, Gao X. Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer. Ann Med. 2024;56(1):2320301.","journal-title":"Ann Med"},{"issue":"3","key":"7407_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.122.263889","volume":"64","author":"R Schollhammer","year":"2023","unstructured":"Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, et al. Comparison of (68)Ga-PSMA-617 PET\/CT and (68)Ga-RM2 PET\/CT in patients with localized prostate Cancer who are candidates for radical prostatectomy: A prospective, Single-Arm, Single-Center, phase II study. J Nucl Med. 2023;64(3):379\u201385.","journal-title":"J Nucl Med"},{"issue":"3","key":"7407_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/pros.21434","volume":"72","author":"M Beer","year":"2011","unstructured":"Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2011;72(3):318\u201325.","journal-title":"Prostate"},{"issue":"12","key":"7407_CR33","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.122.263971","volume":"63","author":"H Duan","year":"2022","unstructured":"Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, et al. Correlation of (68)Ga-RM2 PET with postsurgery histopathology findings in patients with newly diagnosed Intermediate- or High-Risk prostate Cancer. J Nucl Med. 2022;63(12):1829\u201335.","journal-title":"J Nucl Med"},{"key":"7407_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.01.009","volume":"70","author":"TF Fassbender","year":"2019","unstructured":"Fassbender TF, Schiller F, Mix M, Maecke HR, Kiefer S, Drendel V, et al. Accuracy of [(68)Ga]Ga-RM2-PET\/CT for diagnosis of primary prostate cancer compared to histopathology. Nucl Med Biol. 2019;70:32\u20138.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"7407_CR35","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1038\/s41598-021-82995-7","volume":"11","author":"SS Rinne","year":"2021","unstructured":"Rinne SS, Abouzayed A, Gagnon K, Tolmachev V, Orlova A. (66)Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [(66)Ga]Ga-NOTA-PEG(2)-RM26. Sci Rep. 2021;11(1):3631.","journal-title":"Sci Rep"},{"issue":"11","key":"7407_CR36","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","volume":"62","author":"IL Bakker","year":"2021","unstructured":"Bakker IL, Froberg AC, Busstra MB, Verzijlbergen JF, Konijnenberg M, van Leenders G, et al. GRPr antagonist (68)Ga-SB3 PET\/CT imaging of primary prostate Cancer in Therapy-Naive patients. J Nucl Med. 2021;62(11):1517\u201323.","journal-title":"J Nucl Med"},{"issue":"8","key":"7407_CR37","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00259-021-05636-1","volume":"49","author":"DX Qiu","year":"2022","unstructured":"Qiu DX, Li J, Zhang JW, Chen MF, Gao XM, Tang YX, et al. Dual-tracer PET\/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2022;49(8):2821\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"38","key":"7407_CR38","doi-asserted-by":"publisher","first-page":"61955","DOI":"10.18632\/oncotarget.11326","volume":"7","author":"J Qiao","year":"2016","unstructured":"Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, et al. Activation of GRP\/GRP-R signaling contributes to castration-resistant prostate cancer progression. Oncotarget. 2016;7(38):61955\u201369.","journal-title":"Oncotarget"},{"key":"7407_CR39","doi-asserted-by":"crossref","unstructured":"Lee E, Zhang Z, Chen C-C, Choi D, Rivera ACA, Linton E, et al. Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer. bioRxiv [Preprint]. 2024;2024 Mar 20:2024.03.18.585532.","DOI":"10.7554\/eLife.97988"},{"issue":"7","key":"7407_CR40","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/pros.23492","volume":"78","author":"J Shou","year":"2018","unstructured":"Shou J, Zhang Q, Wang S, Zhang D. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study. Prostate. 2018;78(7):491\u20137.","journal-title":"Prostate"},{"issue":"1","key":"7407_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40169-019-0247-4","volume":"8","author":"F Zhao","year":"2019","unstructured":"Zhao F, Wang J, Chen M, Chen D, Ye S, Li X, et al. Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients. Clin Transl Med. 2019;8(1):30.","journal-title":"Clin Transl Med"},{"issue":"2","key":"7407_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, Oprea-Lager DE, Oyen WJ, Rouvi\u00e8re O, Mottet N, Bjartell A. Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):469\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7407_CR43","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s00259-022-06047-6","volume":"50","author":"ZB Ke","year":"2023","unstructured":"Ke ZB, Chen SM, Chen JY, Chen SH, You Q, Sun JB, Xue YT, Sun XL, Wu XH, Zheng QS, Wei Y, Xue XY, Xu N. Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET\/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study. Eur J Nucl Med Mol Imaging. 2023;50(4):1240\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07407-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07407-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07407-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:05:38Z","timestamp":1764219938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07407-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7407"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07407-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave their written informed consents for the publication of all data and images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}},{"value":"The study protocol was approved by the Ethics Committee of Xiangya Hospital. The study adheres to the principles of the Helsinki Declaration and is meticulously executed according to established protocols.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors approved the final version of the manuscript. All the co-authors of this article have consented to its publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We comprehensively introduced the purpose and relevant contents of this study to the patients, ensuring full protection of patiens\u2019 privacy. All patients participated in this study voluntarily.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None declared.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}